Screener
Eton Pharmaceuticals, Inc. ETON Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Eton Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Eton Pharmaceuticals, Inc.’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 4:17 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001437749-26-017064
| Line item | Three months ended / March 31, 2026 | Three months ended / March 31, 2025 |
|---|---|---|
| Cash flows from (used in) operating activities | ||
| Net income (loss) | $1,554 | $(1,572) |
| Adjustments to reconcile net income (loss) to net cash from (used in) operating activities: | ||
| Stock-based compensation | 1,518 | 1,200 |
| Depreciation and amortization | 1,131 | 1,013 |
| Inventory step-up | 350 | 1,142 |
| Excess and obsolete inventory reserve | 227 | 110 |
| Debt discount amortization and non-cash interest expenses | 118 | 294 |
Document
FAQ
- What is Eton Pharmaceuticals, Inc.'s stock-based comp?
- Eton Pharmaceuticals, Inc. (ETON) reported stock-based comp of $1.52M in Q1 2026.
- How has Eton Pharmaceuticals, Inc.'s stock-based comp changed year-over-year?
- Eton Pharmaceuticals, Inc.'s stock-based comp increased by 26.5% year-over-year, from $1.2M to $1.52M.
- What is the long-term trend for Eton Pharmaceuticals, Inc.'s stock-based comp?
- Over 4 years (2021 to 2025), Eton Pharmaceuticals, Inc.'s stock-based comp has grown at a 13.0% compound annual growth rate (CAGR), from $3.38M to $5.51M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Eton Pharmaceuticals, Inc.'s stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude